The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Abstract Background Glioblastoma (GBM) is a fatal brain tumor, lacking effective treatment. Epidermal growth factor receptor (EGFR) is recognized as an attractive target for GBM treatment. However, GBMs have very poor responses to the first- and second-generation EGFR inhibitors. The third-generatio...
Main Authors: | Xuejiao Liu, Xiangyu Chen, Lin Shi, Qianqian Shan, Qiyu Cao, Chenglong Yue, Huan Li, Shengsheng Li, Jie Wang, Shangfeng Gao, Mingshan Niu, Rutong Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-019-1235-7 |
Similar Items
-
A case report of toxic epidermal necrolysis associated with AZD-9291
by: Wang J, et al.
Published: (2018-07-01) -
Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines
by: Tianxiang Chen, et al.
Published: (2019-04-01) -
Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01) -
Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
by: Zhang Y, et al.
Published: (2018-12-01) -
Calcium Regulates HCC Proliferation as well as EGFR Recycling/Degradation and Could Be a New Therapeutic Target in HCC
by: Teresa Maria Elisa Modica, et al.
Published: (2019-10-01)